Certara’s D360 platform enables Arvinas to accelerate lead identification and optimization processes for oncology, neurodegenerative diseases, and therapies for “undruggable” targets
Certara®, the global model-informed drug development and decision support leader, today announced that its discovery research relationship with Arvinas has expanded to include a greater diversity of small molecule drug discovery projects and data sources. Arvinas’ current drug discovery focus areas include metastatic prostate cancer, locally-advanced or metastatic breast cancer, and neurodegenerative diseases.
Arvinas is the pioneer and clinical-stage leader in the exciting new area of targeted protein degradation. Its proprietary PROTAC® (proteolysis-targeting chimera) protein degraders are chimeric, modular small molecules, which harness the body’s natural protein disposal system, the ubiquitin‐proteasome system, to induce the degradation of disease‐causing proteins.
“Arvinas is employing Certara’s D360 scientific informatics platform to increase the speed and efficiency of its lead identification and optimization processes. D360 is specifically designed to allow scientific researchers to access, understand and share drug discovery data quickly,” explained Dr. David Lowis, Senior Director of Product Management at Certara. “Medical research is moving so rapidly, especially in oncology, that gaining access to novel technology and fast, accurate drug discovery results will determine how quickly new medicines can be brought to patients.”
“We need to be able to query, pivot and dive deep into our drug discovery data, and D360 is the best platform we have found for that,” said Dr. Keith Hornberger, Director, Chemistry at Arvinas. “We have increased the number of data sources and complexity of data, which are now seamlessly integrated providing complete transparency to our end users. We currently have around 70 scientists using D360, running over 700 distinct D360 queries. Compared to our previous research informatics solution, D360 is saving us hundreds of hours annually on data analysis. That is an important contribution to our research.”
“The Certara team is tenacious and resourceful. They always find a solution. That’s what has made our relationship so successful,” added Dr. Hornberger.
Designed to meet clients’ specific research goals, D360 features small molecule discovery, biologics discovery, and pre-clinical toolkits for both large and small biopharmaceutical companies.
Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the US FDA in the past six years were supported by Certara software or services. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit www.certara.com.